StockIQpro
NASDAQ:SMMT

Summit Therapeutics Inc.

Track all markets on TradingView
Track all markets on TradingView

Summit Therapeutics Inc. reported net income of −$1.1B in fiscal 2025. Free cash flow was −$323.6M, and the diluted share count rose 4.1%.Summary generated from Summit Therapeutics Inc.'s SEC filings. Latest annual report filed Feb 23, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−206.1%
Debt / equityn/a
Free cash flow−$323.6M
FCF marginn/a
Share count change+4.1%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue2100n/a
Operating income−86−72−610−226n/a
Net income−89−79−615−221−1,080
Free cash flow−73−42−77−142−324

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations